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lnsrao@rediffmailAbstract A simple and rapid liquid chromatography-tandem mass spectrometric (LC-MS/MS)
assay method has been developed and fully validated for simultaneous quantiﬁcation of
pioglitazone and candesartan in human plasma. Irbesartan was used as an internal standard.
The analytes were extracted from human plasma samples by solid-phase extraction technique using
a Strata-X 33 mm polymeric sorbent. The reconstituted samples were chromatographed on a C18
column by using a 80:20 (v/v) mixture of acetonitrile and 0.1% formic acid as the mobile phase at
a ﬂow rate of 0.8 mL/min. The calibration curves obtained were linear (rZ0.99) over the
concentration range of 15–3000 ng/mL for pioglitazone and 5–608 ng/mL for candesartan. The
results of the intra- and inter-day precision and accuracy studies were well within the acceptable
limits. A run time of 2.7 min for each sample made it possible to analyze more than 300 plasma
samples per day. The proposed method was found to be applicable to clinical studies.
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Pioglitazone is an oral antidiabetic agent used in the treatment of
type 2 diabetes. After administration, pioglitazone decreases
insulin resistance in the periphery and liver resulting in increased
insulin dependent glucose disposal and decreased hepatic glucose
output [1,2]. It is used both as monotherapy and in combination
with insulin in the management of type 2 diabetes [3,4].
Pharmacological studies indicate that pioglitazone improves
sensitivity to insulin in muscle and adipose tissues and inhibits
hepatic gluconeogenesis. Candesartan is a selective angiotensin II
type 1 receptor antagonist. The drug ﬁnds most signiﬁcant clinical
Figure 1 Chemical structures of pioglitazone, candesartan and
irbesartan (IS).
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sion is frequently accompanied by type 2 diabetes in the same
patients and hence, many hypertensive patients are subjected to
the combination therapy with an antihypertensive drug and an
antidiabetic drug. The combination of pioglitazone and cande-
sartan exerts more beneﬁcial effects on hypertensive cardiovas-
cular injury in hypertension [7].
As per the literature, several LC-MS/MS methods have been
reported for the determination of pioglitazone and candesartan
individually in biological samples [8–13]. The major disadvan-
tages of the all these methods include complicated and
expensive extraction procedures or long chromatographic run
time. The method proposed by Xue et al. [8] for quantiﬁcation
of pioglitazone in human serum and Levi et al. [9] for
quantiﬁcation of candesartan in human plasma utilizes on-line
sample preparation technique, which is expensive equipment
involving many stringent method development protocols.
Another method reported by Lin et al. [11] for determination
of pioglitazone in human plasma is more sensitive but a time–
cost sample preparation involving liquid–liquid (L–L) extract,
evaporation, drying and reconstitution was used in this method
for sample preparation. Some methods [10–12] which can
satisfy the quantitation of one drug in biological ﬂuids
selectively and sensitively cannot be applied to simultaneous
determination pioglitazone and candesartan.
To date, no LC-MS/MS method has been reported for the
simultaneous determination of pioglitazone and candesartan in
human plasma. For pharmacokinetic and bioequivalence studies
of pioglitazone associated with candesartan, it is recommended
to perform the quantitation of pioglitazone and candesartan
simultaneously. The present work describes a simple, selective
and sensitive method, which employs solid-phase extraction
technique for sample preparation and liquid chromatography
with electropspray ionization-tandem mass spectrometry for
simultaneous quantitation of pioglitazone and candesartan in
human plasma. The application of this assay method to a clinical
pharmacokinetic study in healthy male volunteers following oral
administration of pioglitazone and candesartan is described.2. Experimental
2.1. Materials and reagents
The reference samples of pioglitazone hydrochloride (99.70%)
and candesartan (98.06%) were purchased from Neucon Pharma
Pvt. Ltd, Goa, India and irbesartan (99.44%) used as an internal
standard (IS) in this study, was obtained from Hetero Drugs Ltd,
Hyderabad, India. Chemical structures are presented in Fig. 1.
Water used for the LC-MS/MS analysis was prepared by using
Milli Q water puriﬁcation system procured from Millipore
(Bangalore, India). Acetonitrile and methanol (HPLC grade)
were purchased from J.T. Baker (Phillipsburg, USA). Analytical
grade formic acid was purchased from Merck Ltd (Mumbai,
India). The control human plasma sample was procured from
Cauvery Diagnostics and Blood Bank (Secunderabad, India).
2.2. Instrumentation and chromatographic conditions
An HPLC system (Shimadzu, Kyoto, Japan) consisting of
a Zorbax SB C18 column (50 4.6 mm, 3.5 mm; Agilent
Technologies, Santa Clara, CA, USA), a binary LC-20ADprominence pump, an auto sampler (SIL-HTc) and a solvent
degasser (DGU-20 A3) was used for the study. Aliquots of the
processed samples (20 mL) were injected into the column, which
was kept at ambient temperature. An isocratic mobile phase
consisting of a 80:20 (v/v) mixture of acetonitrile and 0.1%
formic acid was used to separate the analytes and delivered at a
ﬂow rate of 0.8 mL/min into the electrospray ionization chamber
of the mass spectrometer. Quantiﬁcation was achieved with MS–
MS detection in positive ion mode for both the analytes and the
internal standard using an MDS Sciex API-3000 mass spectro-
meter (Foster City, CA, USA) equipped with a Turboion-
sprayTM interface at 500 1C. The ion spray voltage was set at
5500 V. The source parameters viz. the nebulizer gas, curtain gas
and collision gas were set at 4, 12 and 12 psi, respectively. The
compound parameters viz. the declustering potential (DP),
collision energy (CE), entrance potential (EP), focusing potential
(FP) and collision cell exit potential (CXP) were 82, 17, 10, 380,
17 V for pioglitazone, 47, 40, 10, 250, 7 V for candesartan and
46, 35, 10, 250, 10 V for irbesartan. Detection of the ions was
carried out in the multiple-reaction monitoring mode (MRM),
by monitoring the transition pairs of m/z 357.1 precursor ion to
the m/z 134.0 for pioglitazone, m/z 441.3 precursor ion to the m/z
263.1 for candesartan and m/z 429.2 precursor ion to the m/z
207.1 product ion for the IS. Quadrupoles Q1 and Q3 were set
on unit resolution. The analysis data obtained were processed by
Analyst softwareTM (version 1.4.2). As earlier publications have
discussed the details of fragmentation patterns of pioglitazone
[13], candesartan [9] and IS [14], we are not presenting the data
pertaining to this.
2.3. Preparation of plasma standards and quality controls
Stock solutions of pioglitazone, candesartan and the irbesar-
tan were dissolved in methanol at a concentration of 1 mg/mL.
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to produce working standard solutions using a 50:50 (v/v)
mixture of acetonitrile and water as a diluent. Calibration
curve (CC) standard solutions of pioglitazone and candesartan
in blank plasma were prepared by spiking with an appropriate
volume of the working solutions, giving ﬁnal concentrations of
15, 30, 75, 300, 601, 1202, 1800, 2400 and 3000 ng/mL for
pioglitazone, and 5, 10, 30, 60, 120, 240, 360, 487 and 608 ng/mL
for candesartan. The CC samples were analyzed along with the
quality control (QC) samples for each batch of plasma samples.
The QC samples were prepared at ﬁve different concentration
levels of 15 (LLOQ), 40 (LQC), 401 (MQC-1), 1457 (MQC-2)
and 2602 (HQC) ng/mL for pioglitazone and 5 (LLOQ), 15
(LQC), 76 (MQC-1), 303 (MQC-2) and 515 (HQC) ng/mL for
candesartan in blank plasma. All the prepared plasma samples
were stored at 70 1C.
2.4. Sample processing
A 250 mL aliquot of human plasma sample was mixed with
25 mL of the internal standard working solution (1000 ng/mL
of irbesartan). To this, 500 mL of 5% formic acid was added
after vortex mixing for 10 s. The sample mixture was loaded
onto a Strata-X 33 mm polymeric sorbent cartridge (30 mg/
1 mL) that was pre-conditioned with 1.0 mL of methanol
followed by 1.0 mL water. The extraction cartridge was
washed with 1.0 mL of 5% formic acid followed by 1.0 mL
of water. Pioglitazone, candesartan and irbesartan were eluted
with 1.0 mL of mobile phase. Aliquot of 20 mL of the extract
was injected into the LC-MS/MS system.
2.5. Method validation
The validation of the above method was carried out as per
US FDA guidelines [15]. The parameters determined were
selectivity, matrix effect, linearity, precision, accuracy, recov-
ery, stability and dilution integrity. Selectivity was assessed by
comparing the chromatograms of six different batches of
blank plasma obtained from six different sources including
one lipemic and one hemolyzed plasma. Sensitivity was
determined by analyzing six replicates of plasma samples
spiked with the lowest level of the calibration curve concen-
trations. Matrix effect was checked with six different lots of
K2-EDTA plasma. Three replicate samples each of LQC and
HQC were prepared from different lots of plasma (36 QC
samples in total). For checking the linearity standard calibra-
tion curves containing at least nine points (non-zero stan-
dards) were plotted (15–3000 ng/mL for pioglitazone and
5–608 ng/mL for candesartan). In addition, blank plasma
samples were also analyzed to conﬁrm the absence of direct
interferences. Intra-day precision and accuracy were deter-
mined by analyzing six replicates at ﬁve different QC levels on
two different days. Inter-day precision and accuracy were
determined by analyzing six replicates at ﬁve different QC
levels of ﬁve different runs. Recoveries of pioglitazone,
candesartan and irbesartan were determined by comparing
the peak area of extracted analyte standard with the peak area
of non-extracted standard. Recoveries of pioglitazone and
candesartan were determined at a concentration of 40, 15
(LQC), 1457, 303 (MQC-2) and 2602, 515 (HQC) ng/mL,
respectively, whereas for IS recovery was determined atconcentration of 1000 ng/mL. Dilution integrity was per-
formed to extend the upper concentration limit with accep-
table precision and accuracy. Six replicates each at a
concentration of about 1.7 times of the uppermost calibration
standard were diluted two- and four-fold with blank plasma.
The diluted samples were processed and analyzed.
Stability tests were conducted to evaluate the analyte
stability in stock solutions and in plasma samples under
different conditions. The stock solution stability at room
temperature and refrigerated conditions (2–8 1C) was per-
formed by comparing the area response of the analytes
(stability samples) with the response of the sample prepared
from fresh stock solution. Bench top stability (10 h), processed
samples stability (Autosampler stability for 48 h, wet extract
stability for 24 h and reinjection stability for 24 h), freeze-thaw
stability (three cycles), long-term stability (50 day) were
performed at LQC and HQC levels using six replicates at
each level. Samples were considered to be stable if assay values
were within the acceptable limits of accuracy (715% SD) and
precision (r15% RSD).
2.6. Pharmacokinetic study design
A pharmacokinetic study was performed in healthy male
subjects (n¼6). The ethics committee approved the protocol
and the volunteers provided with informed written consent.
Blood samples were collected following oral administration of
pioglitazone (30 mg) and candesartan (16 mg) at pre-dose and
1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 10, 12, 24 and 36 h,
in K2-EDTA vacutainer collection tubes (BD, Franklin, NJ,
USA). The tubes were centrifuged at 3200 rpm for 10 min and
the plasma was collected. The collected plasma samples were
stored at 70 1C till their use. Plasma samples were spiked
with the IS and processed as per the extraction procedure
described earlier. Along with the clinical samples, the QC
samples at low, middle 1, middle 2 and high concentration
levels were also assayed in triplicate. Plasma concentration–
time proﬁle of candesartan was analyzed by non-compart-
mental method using WinNonlin Version 5.1.3. Results and discussion
3.1. Method development
Mass parameters were tuned in both positive and negative
ionization modes for the analytes. Good response was found in
positive ionization mode. Data in the MRM mode were
considered, which showed better selectivity. Chromatographic
conditions, especially the composition of the mobile phase, were
optimized through several trials to achieve good resolution and
increased intensity of the signals of the analytes, as well as short
run time. The presence of a small amount of formic acid in the
mobile phase improved the detection of the analytes. It was
found that a mixture of acetonitrile and 0.1% formic acid (80:20,
v/v) could achieve this purpose and was ﬁnally adopted as the
mobile phase. Zorbax SB C18 (50 4.6 mm, 3.5 mm) column
gave good peak shapes and response even at lowest concentra-
tion level for both the analytes and IS. The mobile phase was
operated at a ﬂow rate of 0.8 mL/min. The retention time of
pioglitazone, candesartan and the IS was low enough (0.7, 1.6
and 0.9 min) allowing a small run time of 2.7 min. A simple
V.K. Karra et al.170solid-phase extraction (SPE) technique was employed for the
sample preparation in this work and provided high recoveries of
the drugs. At the initial stages of this work, several compounds
were tried for ﬁnding out a suitable IS in this analysis and ﬁnally
irbesartan was found to be the best for the purpose.
3.2. Selectivity and chromatography
The degree of interference by endogenous plasma constituents
with the analytes and the IS was assessed by inspection of
chromatograms derived from processed blank plasma sample.
As shown in Figs. 2 and 3, no signiﬁcant direct interference in
the blank plasma traces was observed from endogenous
substances in drug-free plasma at the retention time of the
analytes.
3.3. Sensitivity
The lowest limit of reliable quantiﬁcation for the analytes was
set at the concentration of the LLOQ. The precision and
accuracy at LLOQ concentration were found to be 2.51% and
99.22% for pioglitazone, 2.13% and 96.85% for candesartan.Figure 2 Typical MRM chromatograms of pioglitazone (left panel) an
spiked with IS (B), a LLOQ sample along with IS (C).3.4. Matrix effect
No signiﬁcant matrix effect was observed in all the six batches of
human plasma for the analytes at low and high quality control
concentrations. The precision and accuracy for pioglitazone at
LQC concentration were found to be 1.33% and 102.68%, and
at HQC level they were 1.08% and 99.69%, respectively.
Similarly, the precision and accuracy for candesartan at LQC
concentration were found to be 2.81% and 97.64%, and at HQC
level they were 1.98% and 98.87%, respectively.3.5. Linearity
The nine-point calibration curve was found to be linear over
the concentration range of 15–3000 ng/mL for pioglitazone
and 5–608 ng/mL for candesartan. After comparing the two
weighting models (1/x and 1/x2), a regression equation with a
weighting factor of 1/x2 of the drug to the IS concentration
was found to produce the best ﬁt for the concentration–
detector response relationship for both the analytes in human
plasma. The mean correlation coefﬁcient of the weighted
calibration curves generated during the validation was 0.99.d IS (right panel) in human blank plasma (A), and human plasma
Figure 3 Typical MRM chromatograms of candesartan (left panel) and IS (right panel) in human blank plasma (A), and human plasma
spiked with IS (B), a LLOQ sample along with IS (C).
Table 1 Precision and accuracy data for pioglitazone and candesartan in human plasma samples.
Analyte Concentration
added (ng/mL)
Intra-day precision and accuracy
(n¼12; 6 from each batch)
Inter-day precision and accuracy
(n¼30; 6 from each batch)
Concentration found
(mean; ng/mL)
Precision
(%)
Accuracy
(%)
Concentration found
(mean; ng/mL)
Precision
(%)
Accuracy
(%)
Pioglitazone 15.1 14.3 4.8 94.3 14.3 5.2 94.8
40.1 39.0 2.9 97.3 38.6 3.6 96.4
400.7 372.0 4.1 92.9 381.3 5.8 95.2
1457.0 1400.8 2.5 96.1 1373.7 2.8 94.3
2601.8 2507.2 3.0 96.4 2460.9 2.9 94.6
Candesartan 5.1 5.2 4.0 102.3 5.0 6.2 98.6
15.2 15.8 2.6 104.4 15.5 3.8 102.3
75.8 79.9 2.5 105.4 79.0 3.3 104.1
303.3 320.0 20.0 105.5 316.2 2.7 104.3
514.9 521.5 2.3 101.3 514.5 3.1 99.9
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Table 2 Stability data for pioglitazone and candesartan in human plasma samples (n¼6).
Stability test Pioglitazone Candesartan
QC (spiked
concentration,
ng/mL)
Mean7SD
(ng/mL)
Accuracy/
stability
(%)
Precision
(%)
QC (spiked
concentration,
ng/mL)
Mean7SD
(ng/mL)
Accuracy/
stability
(%)
Precision
(%)
Aautosampler
stability (at 10 1C
for 48 h)
40.1 40.071.6 102.4 3.8 15.2 15.570.3 102.5 2.2
2601.8 2829.47103.7 108.7 4.6 514.9 520.175.2 101.0 1.0
Wet extract stability
(at 2–8 1C for 24 h)
40.1 40.670.5 101.3 1.1 15.2 15.570.3 102.5 2.1
2601.8 2701.4751.2 103.8 1.9 514.9 522.475.9 101.5 1.1
Bench top stability
(10 h at room
temperature)
40.1 39.470.6 98.4 1.4 15.2 15.070.3 99.0 2.3
2601.8 2781.4758.0 106.9 2.1 514.9 520.0710.1 101.0 1.9
Freeze-thaw stability
(three cycles)
40.1 40.87 0.5 101.9 1.3 15.2 15.670.9 102.7 5.6
2601.8 2698.4771.8 103.7 2.7 514.9 523.1712.8 101.6 2.4
Reinjection stability
(24 h)
40.1 37.973.0 94.5 7.9 15.2 16.270.3 106.7 1.6
2601.8 2601.4797.4 100.0 3.7 514.9 543.574.2 105.6 0.8
Long-term stability
(at 70 1C for
50 day)
40.1 40.470.6 100.8 1.5 15.2 14.870.2 97.9 1.1
2601.8 2790.4758.7 107.3 2.1 514.9 501.875.0 97.5 1.0
Figure 4 Mean plasma concentration-time proﬁle of pioglitazone
(A), candesartan (B), in human plasma following oral dosing of piog-
litazone (30 mg) and candesartan (16 mg) tablet to healthy volunteers.
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As shown in Table 1, the precision and accuracy of each
analyte in the intra- and inter-day runs were within 715% at
LQC, MQC-1, MQC-2 and HQC concentrations and within
720% at LLOQ QCs.
3.7. Extraction efﬁciency
Six replicates at low, medium and high quality control concentra-
tion for pioglitazone and candesartan were prepared for recovery
determination. The recoveries of analytes and IS were good
and reproducible. The mean overall recoveries (with the precision
range) of pioglitazone, candesartan and IS were 98.1571.73%
(1.89–5.71%), 77.6673.15% (1.33–3.15%) and 75.5370.85%
(1.19–2.78%), respectively.
3.8. Dilution integrity
The upper concentration limits can be extended to 4800 ng/mL
for pioglitazone and 975 ng/mL for candesartan by 1/2 and 1/4
dilutions with screened human blank plasma. The mean back
calculated concentrations for 1/2 and 1/4 dilution samples were
within 85–115% of their nominal value. The coefﬁcients of
variation (%CV) for 1/2 and 1/4 dilution samples were less
than 10%.
3.9. Stability studies
In the different stability experiments carried out viz. bench top
stability (10 h), autosampler stability (48 h), repeated freeze-
thaw cycles (three cycles), reinjection stability (24 h), wet
extract stability (24 h at 2–8 1C) and long-term stability at
70 1C for 50 day the mean % nominal values of the analytes
Table 3 Pharmacokinetic parameters of pioglitazone and
candesartan (n¼6, Mean7SD).
Parameter Pioglitazone Candesartan
Cmax (ng/mL) 1628.0757.3 156.2715.4
tmax (h) 3.070.5 4.170.6
AUC0t (ng h/mL) 1131971023 15867454
AUC0inf (ng h/mL) 123817865 17157422
t1/2 (h) 5.872.2 10.875.0
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tions for the analytes at their LQC and HQC levels (Table 2).
Thus, the results were found to be within the acceptable limits
during the entire validation.
3.10. Pharmacokinetic study results
In order to verify the sensitivity and selectivity of this method in a
real-time situation, the present method was used to test for
pioglitazone and candesartan concentrations in human plasma
samples collected from healthy male volunteers (n¼6). The mean
plasma concentrations vs time proﬁles of pioglitazone and
candesartan are shown in Fig. 4. The pharmacokinetic para-
meters estimated are shown in Table 3. These values were in close
proximity when compared with earlier reported values [16,17].4. Conclusions
The LC-MS/MS assay method described in this paper is rapid,
simple, speciﬁc and sensitive for quantiﬁcation of pioglitazone
and candesartan in human plasma and is fully validated as per
the FDA guidelines. To the best of our knowledge, this is the
ﬁrst report on simultaneous assay of pioglitazone and cande-
sartan in any of the matrix without compromising on the
reported sensitivity for each analyte. The method was found to
be suitable for pharmacokinetic studies in humans. The simple
solid-phase extraction method gave consistent and reproduci-
ble recoveries for the analytes from plasma. The method
provided good linearity. A sample turnover rate of less than
2.7 min makes it an attractive procedure in high-throughput
bioanalysis of pioglitazone and candesartan.
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